MedWatch

Zealand-share dips because of delay

The stock market reacted heavily to news about a delay in the development of the combination treatment with Zealand Pharma’s Lyxumia and Sanofi’s Lantus.

Foto: Zealand Pharma/PR

A drop-off of 20 %.

That was the reaction from the stock market to Zealand Pharma’s share following an announcement revealing that the combination product involving the Danish biotech company’s invention Lyxumia and insulin-product Lantus from French pharma group Sanofi is delayed and will not be entering phase III studies in 2013 as expected.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier